Autoinjectors Market Size to Reach USD 3.4 Billion by 2030.

Pune, India, February,2019/MRFR Press Release/- Market Research Future has published a half-cooked research report on the Global Autoinjectors Market.

Overview:

The global autoinjectors market is expected to exhibit a CAGR of 18.2% over the forecast period from 2022 to 2030, according to a new report from Market Research Future (MRFR). The global autoinjectors market is studied in detail in the report, including the key drivers and restraints affecting the market’s growth, the leading players operating in the global autoinjectors market, and the leading segments likely to dominate the global autoinjectors market over the forecast period.

Autoinjectors are spring-loaded syringes designed for easy administration upon oneself or by an untrained person on the patient. The key intention behind the manufacturing of autoinjectors is to make the process of injecting the respective drug safer and easier to perform, so that untrained personnel can also do it in case of emergencies. The growing prevalence of chronic diseases such as diabetes and the growing preference among patients for home care solutions for the same is likely to be a major driver for the global autoinjectors market over the forecast period. Insulin injections for diabetes management have to be administered regularly, which may lead to the patient having to come into the hospital every time s/he needs an injection, which can be taxing for people living far away. Growing demand for home-based care and management when dealing with long-term diseases such as diabetes is likely to propel the global autoinjectors market over the forecast period.

The growing prevalence of allergies and subsequent cases of anaphylaxis is also likely to be a major driver for the global autoinjectors market, as autoinjectors are majorly used for injecting epinephrine in case of anaphylaxis.

Segmentation:

The global autoinjectors market has been segmented on the basis of type, therapy, distribution channel, and region.

On the basis of type, the global autoinjectors market has been segmented into disposable autoinjectors and reusable autoinjectors.

By therapy, the global autoinjectors market has been segmented into rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and others.

By distribution channel, the global autoinjectors market has been segmented into retail pharmacies, hospital pharmacies, and others.Regional analysis:

The market has been segmented by region into the Americas, Europe, Asia Pacific, and the Middle East and Africa. The autoinjectors market in the Americas has been segmented into North America and South America; the North American market is further divided into the U.S. and Canada. The European autoinjectors market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The autoinjectors market in Asia Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia Pacific. The autoinjectors market in the Middle East and Africa has been segmented into the Middle East and Africa.

The Americas is likely to maintain dominant position in the global autoinjectors market over the forecast period due to the growing demand for autoinjectors for application in cases of anaphylaxis and diabetes. The growing preference for targeted therapies in North America and the subsequent growth in the development channels of targeted therapies in the region is also likely to be a major driver for the autoinjectors market over the forecast period. The high disposable income of consumers in North America and the widespread advancement of the healthcare sector in the region are also major drivers for the autoinjectors market and are likely to drive the regional market at a solid growth rate over the forecast period. The rising prevalence of autoimmune diseases in North America is also likely to be a major driver for the global autoinjectors market over the forecast period; according to the CDC, more than 54 million Americans suffer from arthritis (2017), leading to a steady rise in the demand for autoinjectors.

Asia Pacific is expected to exhibit rapid growth in the global autoinjectors market over the forecast period due to the growing prevalence of diabetes in the region and the growing awareness about autoinjectors.

Competitive Analysis:

Leading players in the global autoinjectors market include AbbVie Inc., Ypsomed, Becton Dickinson and Company, Consort Medical, SHL Group, Teva Pharmaceutical Industries Ltd., Novartis International AG, Bayer AG, Antares Pharma, Johnson & Johnson Services Inc., Unilife Corporation, Owen Mumford, Amgen Inc., and Eli Lilly and Company.

Industry Updates:

In September 2016, Bayer AG received FDA approval for its BETACONNECT electronic autoinjector, followed by approvals for the myBETAapp mobile app and the BETACONNECT navigator in May 2017.